Stockhead Reports: AdAlta locks in $3.7m to speed up Phase II clinical trials, near-term partnershipsLikeFollowShareShare your feedbackQuestions (0)Post questionYour question will be visible to everyone.Start the conversationAsk AdAlta a question about this update.Discover